Related Experiment Video
Updated: Mar 1, 2026
Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
Published on: February 6, 2018
Exploring high-affinity MAGE-A3-specific T-cell receptors derived from healthy donor PBMCs: A preclinical evaluation
Xueying Wu1, Peiying Wang2, Ning Shen2
1Biomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China; Beijing Key Laboratory for Therapeutic Cancer Vaccines, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
Background:
T cell receptor (TCR) therapy is a promising immunotherapy for cancers, leveraging tumor-associated antigens (TAAs) for targeted treatment. MAGE-A3, a cancer-testis antigen, is highly expressed in multiple malignancies, making it an attractive target. However, efficient identification of high-affinity, tumor-specific TCRs remains a challenge.
Methods:
Healthy donor peripheral blood mononuclear cells (PBMCs) were stimulated ex vivo with multi-epitope mRNA or peptide pools to isolate MAGE-A3-specific TCRs. Functional assays, in vivo xenograft models, and structural modeling were used to evaluate TCR efficacy, specificity, and safety.
Results:
Seven MAGE-A3-specific TCRs were identified, with G0507 showing the highest clinical potential. G0507 TCR-T cells demonstrated robust cytotoxicity against MAGE-A3-expressing tumor cells, minimal cross-reactivity, and significant tumor growth inhibition in xenograft models without toxicity. Structural modeling revealed key residues critical for TCR-pMHC interaction, aiding epitope selection and TCR optimization.
Conclusions:
This study demonstrates the feasibility of deriving functional TCRs from healthy donors and highlights the importance of epitope selection for advancing TCR-based therapies. G0507 represents a promising candidate for clinical development, providing a foundation for future cancer immunotherapy strategies targeting MAGE-A3.
Insights
Researchers identified novel T cell receptors (TCRs) targeting MAGE-A3, a cancer antigen. The G0507 TCR shows promise for effective and safe cancer immunotherapy, with minimal side effects.
Area of Science:
- Immunotherapy
- Oncology
- Molecular Biology
Background:
- T cell receptor (TCR) therapy is a key cancer immunotherapy strategy.
- MAGE-A3, a cancer-testis antigen, is a promising target due to its broad expression in malignancies.
- Identifying high-affinity, tumor-specific TCRs is crucial but challenging.
Purpose of the Study:
- To isolate and characterize MAGE-A3-specific T cell receptors (TCRs) from healthy donors.
- To evaluate the efficacy, specificity, and safety of identified TCRs for cancer treatment.
- To explore structural insights for TCR optimization and epitope selection.
Main Methods:
- Isolation of MAGE-A3-specific TCRs from healthy donor PBMCs via ex vivo stimulation.
- Functional assays and in vivo xenograft models to assess TCR performance.
- Structural modeling to understand TCR-pMHC interactions.
Main Results:
- Seven MAGE-A3-specific TCRs were identified, with G0507 demonstrating significant clinical potential.
- G0507 TCR-T cells exhibited potent cytotoxicity against MAGE-A3+ tumor cells and inhibited tumor growth in vivo.
- Minimal cross-reactivity and no observed toxicity were noted for G0507.
Conclusions:
- Deriving functional TCRs from healthy donors is feasible for cancer immunotherapy.
- Epitope selection is critical for the success of TCR-based therapies.
- The G0507 TCR is a promising candidate for clinical development against MAGE-A3-expressing cancers.
More Related Videos
09:07Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations
Published on: August 22, 2019
11:55Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011